News in brief
Barry Ritz named new chair of CRN Board of Directors
Dr Ritz was elected Chair-Elect in 2019 and will hold the chairman position through 2022, succeeding David Campbell, VP, regulatory affairs NA and global regulatory affairs, Bayer Consumer Healthcare. Campbell will continue to serve on the Board as immediate past chair.
“I’m excited about the coming two years and the opportunities they present for CRN and the dietary supplement industry,” Ritz said. “Our board has just adopted a new strategic plan that will strengthen CRN’s role in developing initiatives that expand awareness of the benefits of these products and consumer access to them. I’m honored to be leading the organization at a time when there is so much interest in better nutrition and health.”
Dr Ritz has been involved in the dietary supplement industry for over 20 years and has served on CRN’s Executive Committee since 2017. For over 12 years he has been working for Atrium Innovations, which was acquired in 2018 by Nestlé Health Science. Dr. Ritz is currently responsible for all R&D functions, including product development and clinical trials, as well as all FDA and FTC-related regulatory functions related to products, product labels and marketing claims.
For a full list of members of CRN’s Board of Directors, please click HERE.
